Skip to main content
Peptides/Cognitive

Pinealon

Grade C

Russian preclinical studies report neuroprotective and anti-aging effects on cognition. Independent replication and Western clinical trials are absent.

Category
Cognitive
Evidence grade
C
Route
Intranasal or subcutaneous
Half-life
Short, hours
Typical dose
1–10 mg
Frequency
Daily
Cycle length
10–20 day cycles, 1–2× per year
Best timing
Morning
Why Pinealon matters

Cognitive resilience (research). Russian preclinical studies report neuroprotective and anti-aging effects on cognition. Independent replication and Western clinical trials are absent.

  • Reported neuroprotection in rodent ischemia models
  • Reduced oxidative stress markers
  • Subjective cognitive and sleep improvements (anecdotal)
Typical dose
1–10 mg
Frequency
Daily
Route
Intranasal or subcutaneous
Evidence
Grade C

Mechanism of Action

Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.

Typical Protocol

Dose
1–10 mg
Frequency
Daily
Duration
10–20 day cycles, 1–2× per year
Timing
Morning
Route
Intranasal or subcutaneous
Half-life
Short, hours

Educational reference only — not medical advice.

Pharmacokinetics & Dosing Rationale

Pinealon is administered intranasal or subcutaneous with an approximate systemic half-life of Short, hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Daily) is designed to match receptor kinetics rather than plasma exposure. Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.

How to Administer

  1. Route: Intranasal or subcutaneous. Typical starting dose 1–10 mg, Daily.
  2. Timing: Morning — keep it the same each dosing day to make effects legible.
  3. Cycle length: 10–20 day cycles, 1–2× per year. Reassess with bloods and symptom logs before repeating.
  4. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Reconstitution & Injection Technique

  1. Reconstitute lyophilised powder with bacteriostatic water (0.9% benzyl alcohol) — sterile water is acceptable but shortens shelf life to ~72 hours.
  2. Typical dilution: add 2 mL of bacteriostatic water to a 5 mg vial → 2.5 mg/mL; a 10-unit insulin syringe mark = 0.25 mg.
  3. Inject the diluent slowly against the vial wall — never onto the powder — and gently swirl. Do not shake; peptides denature under shear.
  4. Once reconstituted, store upright in the refrigerator (2–8 °C) and use within 30 days.
  5. Draw the dose with an insulin syringe (29–31G, 8 mm), swab the site with alcohol, pinch subcutaneous tissue on the abdomen or thigh, inject at 90°.

Sterile technique is not optional. Use a fresh needle for every injection.

Cycling & Stacking Strategy

  • Standard protocol: 1–10 mg, Daily, for 10–20 day cycles, 1–2× per year.
  • Ramp up: start at the lower end of the dose range for the first 7–10 days to gauge tolerance and side effects before titrating.
  • Break periods let receptor sensitivity and endogenous feedback loops normalise — running back-to-back cycles without a wash-out erodes the effect.
  • Common stack: Epithalon, Magnesium glycinate. Introduce one compound at a time so you can attribute effect and side effect.

Who This Is For

Good candidates
  • Adults with a specific, measurable goal aligned to cognitive resilience (research).
  • People who already have baseline bloods, a training routine and a sleep protocol in place.
  • Users who can commit to a full cycle, log the protocol, and re-test biomarkers to evaluate response.
  • Anyone working with a clinician willing to supervise off-label or investigational protocols.
Not appropriate for
  • Anyone with active or recent malignancy, or a strong family cancer history where mechanism is angiogenic or growth-promoting.
  • Pregnant or breastfeeding women — human safety data is absent for almost all research peptides.
  • Adolescents and anyone under 21 whose endocrine axis is still developing.
  • People unwilling to run baseline and post-cycle bloods.
  • Specific contraindications for Pinealon: Active malignancy; Pregnancy.

What to Monitor

Standardised cognitive batteryUse Cambridge Brain Sciences or CANTAB monthly — subjective effects deceive.
Sleep qualityCognitive gains collapse without adequate sleep — track total and REM.
Mood (PHQ-9 / GAD-7)Baseline and every 4 weeks — flag any deterioration early.
Take it with you

Download a printable version of this checklist to log baseline, weekly and post-cycle results.

Reported Benefits

  • Reported neuroprotection in rodent ischemia models
  • Reduced oxidative stress markers
  • Subjective cognitive and sleep improvements (anecdotal)

Safety Profile

Side effects
  • Largely unknown long-term
  • Injection site or nasal irritation
Contraindications
  • Active malignancy
  • Pregnancy
Other bioregulator peptidesOften stacked; interactions not characterized.
Storage & handling
  • Unreconstituted vials: store at 2–8 °C long-term; brief room-temperature excursions during shipping are usually acceptable.
  • Reconstituted vials: refrigerate at 2–8 °C, protect from light, use within 30 days.
  • Freezing: acceptable for unreconstituted powder if long-term storage is required; avoid repeated freeze-thaw cycles.
  • Never use a vial that appears cloudy, discoloured or has visible particulates.

Common Mistakes

  • Chasing a bigger dose instead of consistency — Pinealon outcomes track cumulative exposure, not peak concentration.
  • Skipping baseline bloods, so there is no way to know whether the cycle actually moved a biomarker.
  • Stacking three or four novel compounds at once — you lose the ability to attribute any effect or side effect.
  • Ignoring the training, sleep and nutrition fundamentals that are prerequisites for every peptide protocol.
  • Reusing insulin needles or failing to rotate injection sites — a preventable cause of local reactions and lipohypertrophy.

Evidence Grade — C

Grade C — mechanistic hypothesis and animal or in-vitro data only. No controlled human trials. Treat as experimental; risks are not fully known.

Below are the primary references used to grade Pinealon. Follow the links for full-text where available and cross-check against the current literature.

Frequently Asked Questions

What is the typical Pinealon protocol?+

1–10 mg, Daily, for 10–20 day cycles, 1–2× per year. Route: Intranasal or subcutaneous. Timing: Morning. Half-life: Short, hours.

How does Pinealon work?+

Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.

How long before I see results from Pinealon?+

Most users track a full 10–20 day cycles, 1–2× per year cycle before judging response. Subjective changes can appear within 1–3 weeks, but objective biomarker shifts typically need the full cycle plus repeat labs.

Is Pinealon legal?+

Research chemical; not approved for human therapeutic use.

What are the main side effects of Pinealon?+

Largely unknown long-term; Injection site or nasal irritation.

What should I stack with Pinealon?+

Commonly combined with: Epithalon, Magnesium glycinate. Introduce one compound at a time to preserve attribution.

What biomarkers should I monitor on Pinealon?+

Baseline and post-cycle: full blood count, comprehensive metabolic panel, and category-specific markers for cognitive peptides (see the monitoring section on this page).

Can I run Pinealon back-to-back?+

Off-cycle periods let receptor sensitivity and endogenous feedback normalise. Continuous dosing without a wash-out typically produces diminishing returns and a poorer safety margin.

References

  1. [1]Khavinson VK — Peptide bioregulators and aging Advances in Gerontology, 2014

Further reading: Research library → · Protocols →

AttributePinealonThis pageDihexaRetatrutide
EvidenceGrade CGrade CGrade A
CategoryCognitiveCognitiveMetabolic
Best forCognitive resilience (research)Cognitive plasticity (preclinical)Triple GIP/GLP-1/glucagon agonist
Typical dose1–10 mg8–45 mg (anecdotal)Titrated 2 mg → 4 mg → 8 mg → 12 mg
FrequencyDailyDailyOnce weekly
RouteIntranasal or subcutaneousOral or transdermal (research)Subcutaneous injection
Legal statusResearch chemical; not approved for human therapeutic use.Research chemical. Not approved for human use. Significant unknown oncologic risk.Investigational; not yet FDA-approved. Currently available only via clinical trials.
ActionCurrent pageView →View →